Silicon Valley company 23andMe is a pioneer in personal genetic testing. The decade-old, privately held company based in Mountain View, California and backed by Alphabet's Google Ventures, made a name for itself through direct-to-consumer "spit" tests, kits sent directly to customers at home who ship back a sample of their saliva for genetic analysis to determine whether they are carriers for a range of diseases.
For $199, customers curious about their ancestry, physical traits, personal wellness, and carrier status for certain diseases have access to more than 60 genetic reports offered by 23andMe through genotyping, which is different from full-on DNA sequencing.
"It's like going through the library but opening up each book to certain pages and looking at certain lines," said Erynn Gordon, 23andMe's director of clinical development. "We're looking at specific spots in the genome that we know are more frequently changed in carriers."